BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 25690407)

  • 1. Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients.
    Waters VJ; Stanojevic S; Sonneveld N; Klingel M; Grasemann H; Yau YC; Tullis E; Wilcox P; Freitag A; Chilvers M; Ratjen FA
    J Cyst Fibros; 2015 Nov; 14(6):755-62. PubMed ID: 25690407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations.
    Waters V; Stanojevic S; Klingel M; Chiang J; Sonneveld N; Kukkar R; Tullis E; Ratjen F
    J Cyst Fibros; 2015 Nov; 14(6):770-6. PubMed ID: 26265220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.
    Hoppe JE; Wagner BD; Accurso FJ; Zemanick ET; Sagel SD
    J Cyst Fibros; 2018 Nov; 17(6):760-768. PubMed ID: 29921503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.
    de Boer K; Vandemheen KL; Tullis E; Doucette S; Fergusson D; Freitag A; Paterson N; Jackson M; Lougheed MD; Kumar V; Aaron SD
    Thorax; 2011 Aug; 66(8):680-5. PubMed ID: 21680566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial.
    Aaron SD; Vandemheen KL; Ferris W; Fergusson D; Tullis E; Haase D; Berthiaume Y; Brown N; Wilcox P; Yozghatlian V; Bye P; Bell S; Chan F; Rose B; Jeanneret A; Stephenson A; Noseworthy M; Freitag A; Paterson N; Doucette S; Harbour C; Ruel M; MacDonald N
    Lancet; 2005 Aug 6-12; 366(9484):463-71. PubMed ID: 16084254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.
    Sagel SD; Thompson V; Chmiel JF; Montgomery GS; Nasr SZ; Perkett E; Saavedra MT; Slovis B; Anthony MM; Emmett P; Heltshe SL
    Ann Am Thorac Soc; 2015 May; 12(5):708-17. PubMed ID: 25714657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sputum club cell protein concentration is associated with pulmonary exacerbation in cystic fibrosis.
    Laguna TA; Williams CB; Brandy KR; Welchlin-Bradford C; Moen CE; Reilly CS; Wendt CH
    J Cyst Fibros; 2015 May; 14(3):334-40. PubMed ID: 25456770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia.
    Ratjen F; Waters V; Klingel M; McDonald N; Dell S; Leahy TR; Yau Y; Grasemann H
    Eur Respir J; 2016 Mar; 47(3):829-36. PubMed ID: 26585432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials.
    Mayer-Hamblett N; Saiman L; Lands LC; Anstead M; Rosenfeld M; Kloster M; Fisher L; Ratjen F
    Contemp Clin Trials; 2013 Sep; 36(1):99-105. PubMed ID: 23770109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
    Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
    Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic duration and changes in FEV
    Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
    BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary exacerbations in cystic fibrosis.
    Rabin HR; Butler SM; Wohl ME; Geller DE; Colin AA; Schidlow DV; Johnson CA; Konstan MW; Regelmann WE;
    Pediatr Pulmonol; 2004 May; 37(5):400-6. PubMed ID: 15095322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis.
    Waters V; Atenafu EG; Salazar JG; Lu A; Yau Y; Matukas L; Tullis E; Ratjen F
    J Cyst Fibros; 2012 Jan; 11(1):8-13. PubMed ID: 21849265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers.
    Kraynack NC; Gothard MD; Falletta LM; McBride JT
    Pediatr Pulmonol; 2011 Sep; 46(9):870-81. PubMed ID: 21465675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary exacerbations in cystic fibrosis.
    Stenbit AE; Flume PA
    Curr Opin Pulm Med; 2011 Nov; 17(6):442-7. PubMed ID: 21881509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations.
    Sharma A; Kirkpatrick G; Chen V; Skolnik K; Hollander Z; Wilcox P; Quon BS
    PLoS One; 2017; 12(2):e0171229. PubMed ID: 28178305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical presentations of pulmonary aspergillosis in children with cystic fibrosis - preliminary report.
    Walicka-Serzysko K; Sands D
    Dev Period Med; 2015; 19(1):66-79. PubMed ID: 26003072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria.
    Block JK; Vandemheen KL; Tullis E; Fergusson D; Doucette S; Haase D; Berthiaume Y; Brown N; Wilcox P; Bye P; Bell S; Noseworthy M; Pedder L; Freitag A; Paterson N; Aaron SD
    Thorax; 2006 Nov; 61(11):969-74. PubMed ID: 16844728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.
    Bilton D; Tino G; Barker AF; Chambers DC; De Soyza A; Dupont LJ; O'Dochartaigh C; van Haren EH; Vidal LO; Welte T; Fox HG; Wu J; Charlton B;
    Thorax; 2014 Dec; 69(12):1073-9. PubMed ID: 25246664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease.
    Moss RB; Mayer-Hamblett N; Wagener J; Daines C; Hale K; Ahrens R; Gibson RL; Anderson P; Retsch-Bogart G; Nasr SZ; Noth I; Waltz D; Zeitlin P; Ramsey B; Starko K
    Pediatr Pulmonol; 2005 Mar; 39(3):209-18. PubMed ID: 15573395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.